Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Sichuan Kelun Pharmaceutical Co Ltd (Kelun), a subsidiary of Sichuan Kelun Industrial Group Co Ltd, carries out the business of research, development, production, and distribution of pharmaceutical products. The company's main activities include the manufacturing of infusion products, antibiotics, and various medical devices. Its product portfolio includes infusion solutions, antibiotics, and medical devices such as infusion sets and syringes. Kelun's products serve customers across the healthcare industry, including hospitals and clinics, and are used in applications such as intravenous therapy and infection treatment. The company has operations across China and international markets. Kelun is headquartered in Chengdu, Sichuan, China.
Headquarters
China
Address
No.36, Baihua West Road, Qingyang District, Chengdu, Sichuan, 610071
Website
www.kelun.com
Telephone
86 28 82860516
No of Employees
20,127
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
002422 (SHE)
Revenue (2024)
$2.6B
-15.1%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-42%
(2024 vs 2023)
Market Cap*
$12.1B
Net Profit Margin (2024)
XYZ
-31.7%
(2024 vs 2023)
* As of and is in US$
Sichuan Kelun Pharmaceutical Co Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Infusion Products | Uniflex |
| Non-Infusion Products | Sacituzumab Tirumotecan Injection |
| OTC Products | Trastuzumb Botidotin Injection |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Regulatory Approval | In October, the company received marketing approval from the National Medical Products Administration for its Class 1 new drug, trastuzumab for injection in China. |
| 2025 | Contracts/Agreements | In January, Hubei Kelun Pharmaceutical Trading Co Ltd signed two distribution agreements with Hupan Pharmaceutical (Hubei) Co Ltd, under the agreement Hupan Pharmaceutical will distribute basic large-volume parenteral solutions to healthcare institutions throughout China. |
| 2023 | Plans/Strategy | In June, Sichuan Kelun-Biotech announced its plans to build international commercialization and global clinical development capabilities in the medium to long term. |
Competitor Comparison
| Key Parameters | Sichuan Kelun Pharmaceutical Co Ltd | Yunnan Baiyao Group Co Ltd | Jiangsu Hengrui Pharmaceuticals Co Ltd | CSPC Pharmaceutical Group Ltd | Shandong Xinhua Pharmaceutical Co Ltd |
|---|---|---|---|---|---|
| Headquarters | China | China | China | China | China |
| City | Chengdu | Kunming | Lianyungang | Shijiazhuang | Zibo |
| State/Province | Sichuan | Yunnan | Jiangsu | Hebei | Shandong |
| No. of Employees | 20,127 | 9,286 | 20,602 | 19,700 | 7,240 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Liu Gexin | Chairman | Executive Board | 2003 | 75 |
| Liu Sichuan | General Manager; Director | Executive Board | 2015 | 42 |
| Lai Degui | Chief Financial Officer; Deputy General Manager | Senior Management | 2014 | 55 |
| Liao Yihong | Deputy General Manager | Senior Management | 2022 | 47 |
| Wei Juncai | Deputy General Manager | Senior Management | 2012 | 62 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer